Literature DB >> 9226087

A survey of social outcome in schizophrenia in Tasmania.

K Kirkby1, B Daniels, I Jones, M McInnes.   

Abstract

OBJECTIVE: To survey the social outcome of patients with schizophrenia attending State mental health facilities in southern Tasmania.
METHOD: Using the Statewide Mental Health Register, patients using inpatient and outpatient facilities who received a diagnosis of schizophrenia between 1981 and 1988 were identified (n = 771), and demographic and illness measures, and admissions and length of inpatient stay were compiled. The Life Skills Profile (LSP) was completed by mental health personnel for the 247 who were regular attenders or inpatients in 1991.
RESULTS: Social morbidity as indexed by the LSP was highest in psychiatric hospital inpatients and patients in long-term rehabilitation programs, and lower in patients attending community centres. The majority of patients in suburban settings and attending community centres lived with their families, whereas patients in the inner city or in the rehabilitation service were mainly in hostel accommodation or living alone. Patients with schizophrenia attending State services were of a similar age range but had a longer duration of illness and more admissions, and had spent more days in hospital than patients who were not in regular contact with the service.
CONCLUSIONS: The distribution of social morbidity in schizophrenia confirms that the public health system is supporting a group with high social morbidity. Patients with the highest morbidity are receiving the highest levels of care and intervention.

Entities:  

Mesh:

Year:  1997        PMID: 9226087     DOI: 10.3109/00048679709073851

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN: 0004-8674            Impact factor:   5.744


  1 in total

1.  Predictors of social cognition in patients with schizophrenia.

Authors:  Daniela Mirabilio; Silvia Di Tommaso; Ilaria Riccardi; Massimo Marinelli; Enrico Daneluzzo; Paolo Stratta; Luigi D'Albenzio; Alessandro Rossi
Journal:  Neuropsychiatr Dis Treat       Date:  2006-12       Impact factor: 2.570

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.